Explore the words cloud of the MYELOMANEXT project. It provides you a very rough idea of what is the project "MYELOMANEXT" about.
The following table provides information about the project.
UNIVERSIDAD DE NAVARRA
|Coordinator Country||Spain [ES]|
|Total cost||1˙468˙606 €|
|EC max contribution||1˙468˙606 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2016-09-01 to 2021-08-31|
Take a look of project's partnership.
|1||UNIVERSIDAD DE NAVARRA||ES (PAMPLONA)||coordinator||1˙468˙606.00|
Multiple myeloma (MM) represents a unique model to investigate cancer stem cells (CSCs), circulating tumour cells (CTCs), and the mechanisms of malignant transformation and chemoresistance. Despite the substantial improvement in MM patients’ outcome, the vast majority of patients eventually relapse and the disease remains largely incurable. For those patients failing to achieve deep remissions, biologically targeted research on the ultra-chemoresistant minimal residual disease (MRD) clone may allow us to understand the cellular mechanisms driving chemoresistance, and design novel therapeutic to overcome; importantly, such effort should be equally performed on two additional key players: CSCs and CTCs. On the opposite side, it is unquestionable that a selected group of patients does experience long-term survival irrespectively of the depth of response achieved, but we fail to understand the mechanisms driving sustained disease control. Is it because of persistent residual benign clones? Is it because of immune surveillance? Here, we will integrate next-generation flow cytometry and sequencing to define i) the signature of CTCs and ultra-chemoresistant MRD cells, ii) the hierarchical place of putative CSCs, iii) the genomic landscape of benign vs. malignant clones; and iv) the role of immune surveillance to achieve functional cures. Hence, we will characterize for the first-time-ever the highly-professional subclones responsible for malignant transformation, disease dissemination, and dramatic relapses after optimal response to therapy. Noteworthy, the innovative approach of this scientific proposal strongly relies on the use and expertise of highly-sensitive next-generation flow cytometry, coupled with optimized DNA- and RNA-sequencing for low-cell-numbers, and prospective patient samples longitudinally available within the scope of well-controlled clinical trials. Herein, we believe that all requirements are met to conduct this ground-breaking research program.
|year||authors and title||journal||last update|
Yuji Mishima, Bruno Paiva, Jiantao Shi, Jihye Park, Salomon Manier, Satoshi Takagi, Mira Massoud, Adriana Perilla-Glen, Yosra Aljawai, Daisy Huynh, Aldo M. Roccaro, Antonio Sacco, Marzia Capelletti, Alexandre Detappe, Diego Alignani, Kenneth C. Anderson, Nikhil C. Munshi, Felipe Prosper, Jens G. Lohr, Gavin Ha, Samuel S. Freeman, Eliezer M. Van Allen, Viktor A. Adalsteinsson, Franziska Michor, Jesus F. San Miguel, Irene M. Ghobrial
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
published pages: 218-224, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2017.03.025
|Cell Reports 19/1||2019-06-19|
B Paiva, N Puig, M T Cedena, B G de Jong, Y Ruiz, I Rapado, J Martinez-Lopez, L Cordon, D Alignani, J A Delgado, M C van Zelm, J J M Van Dongen, M Pascual, X Agirre, F Prosper, J I MartÃn-Subero, M-B Vidriales, N C Gutierrez, M T Hernandez, A Oriol, M A Echeveste, Y Gonzalez, S K Johnson, J Epstein, B Barlogie, G J Morgan, A Orfao, J Blade, M V Mateos, J J Lahuerta, J F San-Miguel
Differentiation stage of myeloma plasma cells: biological and clinical significance
published pages: 382-392, ISSN: 0887-6924, DOI: 10.1038/leu.2016.211
P Arana, B Paiva, M-T Cedena, N Puig, L Cordon, M-B Vidriales, N C Gutierrez, F Chiodi, L Burgos, L-L Anglada, J Martinez-Lopez, M-T Hernandez, A-I Teruel, M Gironella, M-A Echeveste, L RosiÃ±ol, R Martinez, A Oriol, J De la Rubia, A Orfao, J Blade, J-J Lahuerta, M-V Mateos, J-F San Miguel
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
published pages: 971-978, ISSN: 0887-6924, DOI: 10.1038/leu.2017.320
B. Paiva, M.-T. Cedena, N. Puig, P. Arana, M.-B. Vidriales, L. Cordon, J. Flores-Montero, N. C. Gutierrez, M.-L. Martin-Ramos, J. Martinez-Lopez, E. M. Ocio, M. T. Hernandez, A.-I. Teruel, L. Rosinol, M.-A. Echeveste, R. Martinez, M. Gironella, A. Oriol, C. Cabrera, J. Martin, J. Bargay, C. Encinas, Y. Gonzalez, J. J. M. Van Dongen, A. Orfao, J. Blade, M.-V. Mateos, J. J. Lahuerta, J. F. San Miguel
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
published pages: 3165-3174, ISSN: 0006-4971, DOI: 10.1182/blood-2016-03-705319
Bruno Paiva, Juana Merino, JesÃºs F. San Miguel
Utility of flow cytometry studies in the management of patients with multiple myeloma
published pages: 511-517, ISSN: 1040-8746, DOI: 10.1097/cco.0000000000000331
|Current Opinion in Oncology 28/6||2019-05-27|
B. Paiva, L. A. Corchete, M.-B. Vidriales, N. Puig, P. Maiso, I. Rodriguez, D. Alignani, L. Burgos, M.-L. Sanchez, P. Barcena, M.-A. Echeveste, M. T. Hernandez, R. Garcia-Sanz, E. M. Ocio, A. Oriol, M. Gironella, L. Palomera, F. De Arriba, Y. Gonzalez, S. K. Johnson, J. Epstein, B. Barlogie, J. J. Lahuerta, J. Blade, A. Orfao, M.-V. Mateos, J. F. San Miguel
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
published pages: 1896-1906, ISSN: 0006-4971, DOI: 10.1182/blood-2015-08-665679
T Jelinek, R Bezdekova, M Zatopkova, L Burgos, M Simicek, T Sevcikova, B Paiva, R Hajek
Current applications of multiparameter flow cytometry in plasma cell disorders
published pages: e617, ISSN: 2044-5385, DOI: 10.1038/bcj.2017.90
|Blood Cancer Journal 7/10||2019-05-27|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYELOMANEXT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MYELOMANEXT" are provided by the European Opendata Portal: CORDIS opendata.